Prestige Biologics shareholders reject 5-for-1 share consolidation proposal at annual meeting

• Prestige Biologics held its annual shareholders’ meeting on Sept. 30, 2026.
• Shareholders adopted the separate financial statements for fiscal 2025-07-01 to 2026-06-30.
• Plans for a 5-for-1 share consolidation were rejected, leaving the capital structure unchanged unless revisited.
• A proposal to change the par value per share was voted down.
• Amendments to the articles of incorporation were passed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930901088), on September 30, 2026, and is solely responsible for the information contained therein.